Takemehome: innovative strategies to integrate prep and doxypep navigation into a nationwide home HIV/STI self-testing program in the united states

Active Grant Awarded

Award ID
R01MH140708
Recipient
Awarding agency
Obligated
$610,601

Award facts

Assistance listing
93.242 Mental Health Research Grants
Completion date 5% complete
Place of performance
City of Industry, CA 91746, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health awarded Public Health Foundation Enterprises, Inc., doing business as Heluna Health, $610,601 on August 28, 2026, under the Mental Health Research Grants program (CFDA 93.242), as Grant R01MH140708. The assistance type is a grant, with $610,601 obligated.

The award funds a hybrid Type 3 effectiveness-implementation study of two interventions designed to increase PrEP and doxycycline post-exposure prophylaxis (DoxPEP) uptake and persistence among testers of the TakeMeHome.org home HIV/STI self-testing platform. The two interventions are direct booking of a virtual visit with a navigator (DB) and DB combined with the PrEPmate interactive text-messaging program (DB + PrEPmate). The study runs across four jurisdictions with high HIV prevalence. Aim 1 calls for interviews with 10-12 site staff each year in these jurisdictions to assess contextual, innovation, and bridging factors that influence linkage of testers to PrEP and DoxPEP services.

Ultimate completion is June 30, 2031. Place of performance is City of Industry, California 91746.

Description

Abstract
Pre-exposure prophylaxis (PREP) use has the potential to substantially reduce new HIV infections throughout the US, but uptake and persistence remain low. Doxycycline post-exposure prophylaxis (DOXYPEP) has been shown to decrease STI rates, particularly syphilis and chlamydia, but few are using IT nationwide. Takemehome.ORG is an online home HIV/STI testing program offered in nearly 30 jurisdictions across the US. Although a substantial proportion of people using takemehome fall into one or more of the high HIV seroincidence priority populations for PREP use, PREP uptake in this population is very low. We propose to leverage the takemehome.ORG platform and test two novel interventions to increase PREP and DOXYPEP uptake and persistence among takemehome testers. We developed a direct-booking page (DB) to allow individuals to schedule a virtual visit with a navigator to facilitate linkage to PREP and DOXYPEP services. In a pilot program, uptake of this service was high, with 90% completing a navigation visit. Additionally, we developed a program to link takemehome users to an interactive text-messaging program, prepmate, to facilitate ongoing PREP navigation and provide adherence support for people starting PREP. In a pilot study at 2 takemehome sites, prepmate had high feasibility and acceptability with nearly a third starting PREP. We propose a hybrid type 3 effectiveness-implementation study of direct-booking with a navigator (DB) or DB + prepmate to increase PREP and DOXYPEP use across 4 jurisdictions with high HIV prevalence using takemehome. In aim 1, we propose to interview 10-12 site staff each year in these jurisdictions to assess inner and outer contextual, innovation, and bridging factors that influence successful linkage of takemehome testers to PREP and DOXYPEP services before and after implementation of DB and prepmate. We will also bring together navigators from collaborating clinics to learn from each other on how best to implement these interventions in a community of practice. In aim 2, we will enroll 300 takemehome users who express interest in PREP into a 3-arm study and randomly assign them to 1) DB alone (N=100); 2) DB + prepmate (N=100); or standard of care (linkage to the website of a local PREP clinic, N=100). Study participants will be followed for 9 months, and primary outcomes will include PREP uptake and persistence assessed by electronic health record data (EHR) of participating clinics. Secondary outcomes will include objective measures of PREP uptake and persistence (tenofovir diphosphate in dried blood spots, pictures of medication bottles) and EHR and self-reported DOXYPEP uptake and persistence. Lastly, in aim 3, we will assess the cost and cost-effectiveness of both interventions. At the end of the study, we will have rigorously evaluated the implementation and effectiveness of two innovative strategies to facilitate PREP and DOXYPEP use among home HIV/STI testers in the US.

Quick answers

Who received award R01MH140708?

R01MH140708 was awarded to Public Health Foundation Enterprises, Inc. by National Institute of Mental Health (National Institutes of Health) on August 28, 2026.

How much is award R01MH140708 worth?

$610,601 has been obligated on R01MH140708.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award